Additional information to Research Letter "Immunogenicity of Cephalosporin Components in Non-IgE Mediated Cephalosporin Allergy"

<p>The file contains the following information:</p><p><strong>Additional information</strong></p><p><strong>Description</strong></p><p><strong>Page</strong></p><p>Materials and Methods</p><p>Study materials, syntheses of degradation products and enzyme-linked immunospot assay used in the study</p><p>1-3</p><p>Table 1</p><p>In vitro reactivity to different components of ceftriaxone degradation products in patients with positive ELISpot to ceftriaxone or cephalosporine with similar R1 side chain to ceftriaxone (N=21), categorized by underlying diseases and drug allergic phenotypes</p><p>4</p><p>Table 2</p><p>Clinical characteristics of patients with a confirmed non-IgE mediated hypersensitivity reaction to ceftriaxone or cephalosporin with a similar R1 side chain to ceftriaxone</p><p>5-6</p><p>Table 3</p><p>Frequencies of IFN-γ releasing cells and proportions of positive IFN-γ ELISpot assay upon stimulation with the suspected culprit drugs and different cephalosporins in patients with a history of non-IgE mediated reaction to ceftriaxone or cephalosporins with a similar R1 side chain (N= 21)</p><p>7-9</p><p>Figure captions and Figure legends</p><p>&nbsp;</p><p>Figure captions and figure legends for figures 1, 2, 3A, 3B, and 4.</p><p>&nbsp;</p><p>10</p><p>&nbsp;</p><p>Figure 1</p><p>&nbsp;</p><p>Mass spectrum results of the synthesized octalysine-ceftriaxone conjugates</p><p>&nbsp;</p><p>&nbsp;Figure 2</p><p>Chemical structures of cephalosporin components in this study</p><p>&nbsp;</p><p>Fig 3</p><p>Representative figures of IFN-γ releasing cells after stimulating PBMCs with different cephalosporins and their components, as demonstrated by ELISpot assay in two patients with a history of ceftriaxone-induced DRESS. Figure 3A shows the results for a single cephalosporin reactor, and Figure 3B shows the results for a multiple cephalosporin reactor.</p><p>&nbsp;</p><p>Fig 4</p><p>The frequencies of IFN-γ releasing cells and proportions of positive IFN-γ ELISpot assay upon stimulation with the suspected culprit drugs, other cephalosporins, and different components in patients with a history of non-IgE mediated reaction to ceftriaxone or cephalosporins with a similar R1 side chain (N= 21)</p><p>&nbsp;</p><p>&nbsp;</p>